日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Safety and Pharmacokinetics of Repeat Dosing of Long-Acting SARS-CoV-2 Antibodies Tixagevimab/Cilgavimab (AZD7442): Results from the PROVENT Sub-study

长效SARS-CoV-2抗体Tixagevimab/Cilgavimab (AZD7442)重复给药的安全性和药代动力学:PROVENT子研究结果

Ustianowski, Andrew; Levin, Myron J; De Wit, Stephane; Launay, Odile; Veekmans, Bernard; Rampling, Tommy; Sullivan, James G; Vishnepolsky, Mark; Wijewardane, Priyantha; Fawadleh, Yousef; Zhang, Huixia; Li, Meng; Wickramarachchi, Dilki; Sharbaugh, Audrey; Beavon, Rohini; Thissen, Jesse; Hirao, Lauren; Dzutseva, Vitalina; Seegobin, Seth; Streicher, Katie; Kiazand, Alexandre; Esser, Mark T; Chang, Lee-Jah; Perez, John L; Cohen, Taylor S

661. Phase 1, dose-escalation trial of the safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies (DMAb) in healthy adults

661. SARS-CoV-2 DNA编码单克隆抗体(DMAb)在健康成人中的安全性和药代动力学I期剂量递增试验

Dimnjaković, Jelena; Buble, Tamara; Brborović, Ognjen; Tebas, Pablo; Patel, Ami; Agnes, Joseph; Parzych, Elizabeth M; Baer, Amanda; Caturla, Maria; Ghosh, Sukanya; Purwar, Mansi; Bedanova, Nicole; Tsang, chungdhak; Morales, Knashawn; Amante, Dinah; Fisher, Paul D; Francica, Joe; Humeau, Laurent; Pallesen, Jesper; Eric Leon, Paul; Esser, Mark T; Smith, Trevor R F; Weiner, David B

A SARS-CoV-2 variant‑adjusted threshold of protection model for monoclonal antibody pre-exposure prophylaxis against COVID-19

基于SARS-CoV-2变异株调整的单克隆抗体暴露前预防COVID-19的保护阈值模型

Edge, Rhiannon; Matthews, Sam; Ahani, Bahar; Aksyuk, Anastasia A; Clegg, Lindsay; Perez, John L; Esser, Mark T; Chang, Lee-Jah; Hirsch, Ian; Villafana, Tonya; Pura, John; Stepanov, Oleg; Streicher, Katie; White, Tom; Cohen, Taylor S; Follmann, Dean; Gilbert, Peter B; Seegobin, Seth

Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escape

预先优化临床抗体,使其能够广泛中和SARS-CoV-2变异株并增强其抵抗病毒逃逸的能力

Zhu, Fangqiang; Rajan, Saravanan; Hayes, Conor F; Kwong, Ka Yin; Goncalves, Andre R; Zemla, Adam T; Lau, Edmond Y; Zhang, Yi; Cai, Yingyun; Goforth, John W; Landajuela, Mikel; Gilchuk, Pavlo; Kierny, Michael; Dippel, Andrew; Amofah, Bismark; Kaplan, Gilad; Cadevilla Peano, Vanessa; Morehouse, Christopher; Sparklin, Ben; Gopalakrishnan, Vancheswaran; Tuffy, Kevin M; Nguyen, Amy; Beloor, Jagadish; Kijak, Gustavo; Liu, Chang; Dijokaite-Guraliuc, Aiste; Mongkolsapaya, Juthathip; Screaton, Gavin R; Petersen, Brenden K; Desautels, Thomas A; Bennett, Drew; Conti, Simone; Segelke, Brent W; Arrildt, Kathryn T; Kaul, Samantha; Grzesiak, Emilia A; da Silva, Felipe Leno; Bates, Thomas W; Earnhart, Christopher G; Hopkins, Svetlana; Sundaram, Shivshankar; Esser, Mark T; Francica, Joseph R; Faissol, Daniel M

Lower Respiratory Tract Infections Following Respiratory Syncytial Virus Monoclonal Antibody Nirsevimab Immunization Versus Placebo: Analysis From a Phase 3 Randomized Clinical Trial (MELODY)

呼吸道合胞病毒单克隆抗体Nirsevimab免疫接种与安慰剂治疗下呼吸道感染的疗效比较:一项3期随机临床试验(MELODY)的分析

Arbetter, Doug; Gopalakrishnan, Vancheswaran; Aksyuk, Anastasia A; Ahani, Bahar; Chang, Yue; Dagan, Ron; Esser, Mark T; Hammitt, Laura L; Mankad, Vaishali S; Saez-Llorens, Xavier; Shen, David; Leach, Amanda; Kelly, Elizabeth J; Villafana, Tonya; Wilkins, Deidre

Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodies

ACTIV-2 研究中,Tixagevimab/cilgavimab 或安慰剂治疗 COVID-19 的安全性、药代动力学以及中和抗体和抗药抗体

Bender Ignacio, Rachel A; Chew, Kara W; Moser, Carlee; Currier, Judith S; Eron, Joseph J; Javan, Arzhang Cyrus; Giganti, Mark J; Ritz, Justin; Gibbs, Michael; Kouekam, Hervé Tchouakam; Esser, Mark T; Daar, Eric S; Choudhary, Manish; Deo, Rinki; Fletcher, Courtney V; Li, Jonathan Z; Hughes, Michael D; Smith, Davey; Wohl, David Alain

Author Correction: Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants

作者更正:尼塞维单抗给药后中和性RSV抗体的持久性以及婴儿对RSV感染的自然免疫反应的诱导

Wilkins, Deidre; Yuan, Yuan; Chang, Yue; Aksyuk, Anastasia A; Núñez, Beatriz Seoane; Wählby-Hamrén, Ulrika; Zhang, Tianhui; Abram, Michael E; Leach, Amanda; Villafana, Tonya; Esser, Mark T

Safety, Efficacy and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Trial

AZD7442(Tixagevimab/Cilgavimab)治疗轻度至中度COVID-19的安全性、有效性和药代动力学:TACKLE试验的15个月最终分析

Hobbs, F D Richard; Montgomery, Hugh; Padilla, Francisco; Simón-Campos, Jesus Abraham; Arbetter, Douglas; Seegobin, Seth; Kiazand, Alexandre; Streicher, Katie; Martinez-Alier, Nuria; Cohen, Taylor S; Esser, Mark T

Efficacy, Safety, and Pharmacokinetics of AZD7442 (Tixagevimab/Cilgavimab) for Prevention of Symptomatic COVID-19: 15-Month Final Analysis of the PROVENT and STORM CHASER Trials

AZD7442(Tixagevimab/Cilgavimab)预防有症状COVID-19的疗效、安全性和药代动力学:PROVENT和STORM CHASER试验的15个月最终分析

Levin, Myron J; Ustianowski, Andrew; De Wit, Stephane; Beavon, Rohini; Thissen, Jesse; Seegobin, Seth; Dey, Kanika; Near, Karen A; Streicher, Katie; Kiazand, Alexandre; Esser, Mark T

Accelerating therapeutics development during a pandemic: population pharmacokinetics of the long-acting antibody combination AZD7442 (tixagevimab/cilgavimab) in the prophylaxis and treatment of COVID-19

疫情期间加速治疗药物研发:长效抗体组合AZD7442(tixagevimab/cilgavimab)在COVID-19预防和治疗中的群体药代动力学研究

Clegg, Lindsay E; Stepanov, Oleg; Schmidt, Henning; Tang, Weifeng; Zhang, Huixia; Webber, Chris; Cohen, Taylor S; Esser, Mark T; Någård, Mats